Published in Histopathology on January 01, 2012
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Evolutionary medicine: its scope, interest and potential. Proc Biol Sci (2012) 1.94
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
Lack of evidence of HPV etiology of prostate cancer following radical surgery and higher frequency of the Arg/Pro genotype in Turkish men with prostate cancer. Int Braz J Urol (2017) 1.39
A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Prostate (2013) 1.09
Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics (2012) 1.08
In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics (2013) 1.06
Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget (2013) 1.06
The role of chronic inflammation in obesity-associated cancers. ISRN Oncol (2013) 1.04
Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res (2013) 1.04
Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci (2013) 1.03
Multilocus sequence typing (MLST) analysis of Propionibacterium acnes isolates from radical prostatectomy specimens. Prostate (2012) 1.02
PSGR promotes prostatic intraepithelial neoplasia and prostate cancer xenograft growth through NF-κB. Oncogenesis (2014) 0.98
Immune Infiltration and Prostate Cancer. Front Oncol (2015) 0.98
TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. Oncotarget (2015) 0.98
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer (2013) 0.96
Infections and inflammation in prostate cancer. Am J Clin Exp Urol (2013) 0.95
Epigenetic susceptibility factors for prostate cancer with aging. Prostate (2013) 0.94
Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules. PLoS One (2014) 0.93
MSMB variation and prostate cancer risk: clues towards a possible fungal etiology. Prostate (2014) 0.93
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol (2014) 0.92
Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Prostate (2015) 0.91
Nonsteroidal anti-inflammatory drugs and prostatic diseases. Biomed Res Int (2014) 0.91
Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol (2014) 0.89
Role of miRNA let-7 and its major targets in prostate cancer. Biomed Res Int (2014) 0.89
NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis. Cancer Res (2014) 0.89
Future directions in the prevention of prostate cancer. Nat Rev Clin Oncol (2013) 0.88
Cancer/testis antigen PAGE4, a regulator of c-Jun transactivation, is phosphorylated by homeodomain-interacting protein kinase 1, a component of the stress-response pathway. Biochemistry (2014) 0.88
Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients. Int J Oncol (2012) 0.87
Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. BJU Int (2014) 0.87
Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. Virchows Arch (2014) 0.87
Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs (2015) 0.86
Coffee consumption and the risk of prostate cancer: the Ohsaki Cohort Study. Br J Cancer (2013) 0.86
The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res Rep Urol (2012) 0.86
Identification of secretaglobin Scgb2a1 as a target for developmental reprogramming by BPA in the rat prostate. Epigenetics (2015) 0.86
Competing views on cancer. J Biosci (2014) 0.86
Are strict vegetarians protected against prostate cancer? Am J Clin Nutr (2015) 0.86
Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. Br J Cancer (2014) 0.86
Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model. J Steroid Biochem Mol Biol (2014) 0.86
Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease. Oxid Med Cell Longev (2012) 0.85
High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy. World J Urol (2015) 0.84
Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF β2. Mol Carcinog (2014) 0.83
Effect of n-3 and n-6 unsaturated fatty acids on prostate cancer (PC-3) and prostate epithelial (RWPE-1) cells in vitro. Lipids Health Dis (2013) 0.83
Polyomavirus BK and prostate cancer: an unworthy scientific effort? Oncoscience (2014) 0.83
Procyanidin B2 3,3(″)-di-O-gallate, a biologically active constituent of grape seed extract, induces apoptosis in human prostate cancer cells via targeting NF-κB, Stat3, and AP1 transcription factors. Nutr Cancer (2013) 0.82
Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer. Biomed Res Int (2015) 0.82
Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways. PLoS One (2013) 0.82
Prostate cancer: the need for biomarkers and new therapeutic targets. J Zhejiang Univ Sci B (2014) 0.82
Polymorphisms in NFKB1 and NFKBIA Genes Modulate the Risk of Developing Prostate Cancer among Han Chinese. Med Sci Monit (2015) 0.82
Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer. Oncotarget (2016) 0.81
Prostatitis, other genitourinary infections and prostate cancer: results from a population-based case-control study. World J Urol (2015) 0.81
Meta-Analysis of Long-Chain Omega-3 Polyunsaturated Fatty Acids (LCω-3PUFA) and Prostate Cancer. Nutr Cancer (2015) 0.81
Characterization of a Gene Expression Signature in Normal Rat Prostate Tissue Induced by the Presence of a Tumor Elsewhere in the Organ. PLoS One (2015) 0.81
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Rep (2016) 0.81
In vitro and in vivo model systems used in prostate cancer research. J Biol Methods (2015) 0.81
Prostate cancer and new insights in angiogenesis. Front Oncol (2014) 0.81
Characterization of autoimmune inflammation induced prostate stem cell expansion. Prostate (2015) 0.81
Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget (2016) 0.81
Identification of Pathogen Signatures in Prostate Cancer Using RNA-seq. PLoS One (2015) 0.81
Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice. PLoS One (2012) 0.80
Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. Prostate (2016) 0.80
Evidence supporting the association of polyomavirus BK genome with prostate cancer. Med Microbiol Immunol (2013) 0.79
A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. Cancer Immunol Res (2015) 0.78
Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. Curr Gerontol Geriatr Res (2014) 0.78
Fat intake after prostate cancer diagnosis and mortality in the Physicians' Health Study. Cancer Causes Control (2015) 0.78
Prostate-associated gene 4 (PAGE4), an intrinsically disordered cancer/testis antigen, is a novel therapeutic target for prostate cancer. Asian J Androl (2016) 0.78
Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans. Front Immunol (2016) 0.78
Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study. Prostate Cancer Prostatic Dis (2016) 0.78
ARLTS1 and prostate cancer risk--analysis of expression and regulation. PLoS One (2013) 0.77
Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. Cell Rep (2016) 0.77
Molecular signaling involving intrinsically disordered proteins in prostate cancer. Asian J Androl (2016) 0.77
Linking obesogenic dysregulation to prostate cancer progression. Endocr Connect (2015) 0.77
Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments. Cancer Gene Ther (2014) 0.77
Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. Cancer Res (2014) 0.77
Vasectomy and prostate cancer risk: a historical synopsis of undulating false causality. Res Rep Urol (2016) 0.77
Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) (2015) 0.77
Isolation and analysis of discreet human prostate cellular populations. Differentiation (2015) 0.77
Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets. Int J Mol Sci (2016) 0.76
Relationship between vegetable and carotene intake and risk of prostate cancer: the JACC study. Br J Cancer (2013) 0.76
Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study. BMC Cancer (2016) 0.76
Toll-like receptor-associated sequence variants and prostate cancer risk among men of African descent. Genes Immun (2013) 0.76
A Perspective on Prostate Carcinogenesis and Chemoprevention. Curr Pharmacol Rep (2015) 0.76
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-DNA adducts in benign prostate and subsequent risk for prostate cancer. Int J Cancer (2013) 0.76
A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II. Cancer Epidemiol Biomarkers Prev (2014) 0.76
Immune Therapy for Prostate Cancer. Cancer J (2016) 0.76
Vasectomy: potential links to an increased risk of aggressive prostate cancer? Expert Rev Anticancer Ther (2015) 0.75
The impact of genetic variants in inflammatory-related genes on prostate cancer risk among men of African Descent: a case control study. Hered Cancer Clin Pract (2013) 0.75
Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy. BMC Cancer (2016) 0.75
Glucose Metabolism in the Progression of Prostate Cancer. Front Physiol (2017) 0.75
Metabolic syndrome diagnosis and widespread high grade prostatic intraepithelial neoplasia significantly increase prostate cancer risk: results from a multicenter biopsy study. BMC Cancer (2016) 0.75
Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients. PLoS One (2016) 0.75
Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy. Asian J Androl (2015) 0.75
Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice. PLoS One (2016) 0.75
Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. Oncotarget (2016) 0.75
Multiple therapeutic and preventive effects of 3,3'-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia. J Biomed Res (2014) 0.75
Exposure of Prostate to Lipopolysaccharide and Hypoxia Potentiates Neoplastic Behavior and Risk for Prostate Carcinogenesis In Vivo. Int Sch Res Notices (2014) 0.75
A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) (2016) 0.75
Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)-Induced Cancer at Multiple Sites. Cancer Prev Res (Phila) (2015) 0.75
SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas. Hum Pathol (2015) 0.75
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol (2007) 12.20
Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity (2006) 10.53
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Prostate cancer. N Engl J Med (2003) 5.91
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 5.50
NIH consensus definition and classification of prostatitis. JAMA (1999) 5.35
Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol (2005) 5.27
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science (2006) 4.58
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A (1997) 4.20
Regulatory T cells in cancer. Blood (2006) 3.56
Recombinant origin of the retrovirus XMRV. Science (2011) 3.54
Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 3.39
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int (1999) 3.18
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev (2002) 2.99
Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr (2000) 2.92
Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology (2010) 2.75
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Mouse DNA contamination in human tissue tested for XMRV. Retrovirology (2010) 2.65
Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst (2009) 2.50
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
An endogenous murine leukemia viral genome contaminant in a commercial RT-PCR kit is amplified using standard primers for XMRV. Retrovirology (2010) 2.27
Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate (2000) 2.19
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol (2000) 2.11
Epidemiologic association between prostatitis and prostate cancer. Urology (2002) 2.05
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev (2001) 2.03
Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 2.00
XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res (2007) 1.94
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res (2006) 1.76
Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology (2000) 1.71
Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res (2001) 1.67
Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol (2005) 1.66
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res (2008) 1.64
Th17 cells in cancer: help or hindrance? Carcinogenesis (2011) 1.63
Prostatic calculi: a review. Prostate (1985) 1.62
Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology (1995) 1.62
Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol (2002) 1.61
Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate (2003) 1.59
The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res (1997) 1.57
Acne in adolescence and cause-specific mortality: lower coronary heart disease but higher prostate cancer mortality: the Glasgow Alumni Cohort Study. Am J Epidemiol (2005) 1.57
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer (2009) 1.56
DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Carcinogenesis (1999) 1.55
DNA extraction columns contaminated with murine sequences. PLoS One (2011) 1.55
Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol (2006) 1.53
Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res (2009) 1.51
Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology (2000) 1.48
Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res (2005) 1.45
Prevalence of Propionibacterium acnes in diseased prostates and its inflammatory and transforming activity on prostate epithelial cells. Int J Med Microbiol (2010) 1.45
Severe infections caused by Propionibacterium acnes: an underestimated pathogen in late postoperative infections. Yale J Biol Med (1998) 1.44
Fat and meat intake and prostate cancer risk: the multiethnic cohort study. Int J Cancer (2007) 1.43
Chlamydia trachomatis: probable cause of prostatitis. Int J STD AIDS (1998) 1.42
Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer (2009) 1.41
Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate (2009) 1.37
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res (2007) 1.37
Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev (2006) 1.34
Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States. Am J Epidemiol (2009) 1.34
Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol (2010) 1.33
Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr (2008) 1.30
COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis (2004) 1.30
Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.29
Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int (2010) 1.29
Inflammation, infection, and prostate cancer. Curr Opin Urol (2008) 1.29
Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol (2008) 1.28
Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev (2007) 1.28
Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer (2003) 1.25
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. J Urol (2006) 1.25
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology (2008) 1.24
Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer (2009) 1.24
Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc Natl Acad Sci U S A (2009) 1.24
Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol (2010) 1.23
The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res (2007) 1.23
Meat and meat mutagens and risk of prostate cancer in the Agricultural Health Study. Cancer Epidemiol Biomarkers Prev (2008) 1.23
Molecular pathology of prostate cancer. J Clin Pathol (2005) 1.22
Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.21
Cytotoxic necrotizing factor type 1-positive Escherichia coli causes increased inflammation and tissue damage to the prostate in a rat prostatitis model. Infect Immun (2001) 1.18
Direct visualization of Propionibacterium acnes in prostate tissue by multicolor fluorescent in situ hybridization assay. J Clin Microbiol (2007) 1.18
Acute bacterial inflammation of the mouse prostate. Prostate (2011) 1.16
Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One (2010) 1.16
Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res (2009) 1.13
The biology of interleukin-6. Chem Immunol (1992) 1.13
PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis (2009) 1.13
Association between the presence of bacterial 16S RNA in prostate specimens taken during transurethral resection of prostate and subsequent risk of prostate cancer (Sweden). Cancer Causes Control (2006) 1.12
Xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer cells likely represents a laboratory artifact. Oncotarget (2011) 1.12
Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia (2006) 1.11
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 2.00
Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol (2002) 1.95
XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther (2004) 1.82
Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79
Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res (2006) 1.76
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
Cyclooxygenases in cancer: progress and perspective. Cancer Lett (2004) 1.74
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol (2003) 1.65
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.61
Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev (2004) 1.60
A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59
Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol (2011) 1.58
GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem (2004) 1.58
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer (2009) 1.56
Epigenetic alterations in human prostate cancers. Endocrinology (2009) 1.55
Practical methods for tissue microarray construction. Methods Mol Med (2005) 1.54
ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol (2011) 1.54
MYC and Prostate Cancer. Genes Cancer (2010) 1.54
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
Telomere length as a risk factor for hereditary prostate cancer. Prostate (2013) 1.50
Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate (2009) 1.45
Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol (2004) 1.44
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res (2013) 1.43
Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate (2004) 1.43
GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate (2008) 1.42
Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol (2010) 1.39
Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate (2005) 1.38
Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci (2007) 1.37
Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol (2012) 1.35
Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate (2005) 1.34
Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate (2009) 1.33
Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.29
Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control (2010) 1.29
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer (2012) 1.28
Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev (2007) 1.28
DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res (2010) 1.24
Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc Natl Acad Sci U S A (2009) 1.24
Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol (2010) 1.23
Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res (2005) 1.23
Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma. Am J Surg Pathol (2003) 1.23
The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res (2007) 1.23
Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines. PLoS One (2011) 1.22
Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A (2007) 1.22
Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clin Cancer Res (2011) 1.21
Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol (2009) 1.17
MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol (2011) 1.15
Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. Mod Pathol (2008) 1.15
Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. Prostate (2008) 1.14
Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol (2011) 1.14
The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells. Prostate (2010) 1.14
Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev (2005) 1.13
Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am J Pathol (2011) 1.12
Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol (2008) 1.11
Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol (2006) 1.11
Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology (2002) 1.10
Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate (2008) 1.10
Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res (2003) 1.09
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res (2010) 1.09
A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Prostate (2013) 1.09
XMRV and prostate cancer--a 'final' perspective. Nat Rev Urol (2012) 1.08
Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol (2004) 1.08
Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol (2012) 1.07
The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res (2012) 1.07
Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol (2004) 1.06
Recent advances in telomere biology: implications for human cancer. Curr Opin Oncol (2004) 1.03
Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov (2013) 1.03
Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. Urology (2007) 1.03
Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Hum Pathol (2011) 1.02